{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:21:32Z","timestamp":1786998092821,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.vph.2015.03.018","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T16:17:04Z","timestamp":1428769024000},"page":"6-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["A brief review on high on-aspirin residual platelet reactivity"],"prefix":"10.1016","volume":"67-69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7543-475X","authenticated-orcid":false,"given":"A.A.","family":"Pettersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Arnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Seljeflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.03.018_bb0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2015.03.018_bb0010","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vph.2015.03.018_bb0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH08-01-0056","article-title":"Clinical implications of aspirin resistance","volume":"100","author":"Zimmermann","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0020","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.03.018_bb0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ehj.2003.10.013","article-title":"Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology","volume":"25","author":"Patrono","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2015.03.018_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Collaboration","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2015.03.018_bb0035","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1046\/j.1538-7836.2003.00354.x","article-title":"Aspirin resistance: a revival of platelet aggregation tests?","volume":"1","author":"De Gaetano","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.thromres.2005.10.011","article-title":"Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6months prospective study","volume":"118","author":"Gianetti","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0050","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.amjcard.2006.05.041","article-title":"Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events","volume":"98","author":"Marcucci","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0055","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2015.03.018_bb0060","first-page":"38","article-title":"Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis","volume":"75","author":"Craven","year":"1953","journal-title":"Miss Valley Med J"},{"key":"10.1016\/j.vph.2015.03.018_bb0065","first-page":"213","article-title":"Prevention of coronary and cerebral thrombosis","volume":"78","author":"Craven","year":"1956","journal-title":"Miss Valley Med J"},{"key":"10.1016\/j.vph.2015.03.018_bb0070","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0140-6736(49)91829-2","article-title":"Aspirin in the treatment of vascular diseases","volume":"2","author":"Gibson","year":"1949","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.03.018_bb0075","first-page":"IV24","article-title":"Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents","volume":"21","author":"Smith","year":"1990","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.03.018_bb0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"key":"10.1016\/j.vph.2015.03.018_bb0085","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.03.018_bb0090","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2015.03.018_bb0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0100","first-page":"E606","article-title":"Acetylsalicylic acid hydrolase of gastric mucosa","volume":"234","author":"Spenney","year":"1978","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.2042-7158.1989.tb06487.x","article-title":"Human liver and plasma aspirin esterase","volume":"41","author":"Williams","year":"1989","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.vph.2015.03.018_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3109\/00498258609043527","article-title":"The metabolism of aspirin in man: a population study","volume":"16","author":"Hutt","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/j.vph.2015.03.018_bb0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","article-title":"Dose- and time-dependent antiplatelet effects of aspirin","volume":"95","author":"Perneby","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0120","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/0002-9149(91)90379-Y","article-title":"Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists","volume":"68","author":"FitzGerald","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1172\/JCI109379","article-title":"Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence","volume":"63","author":"Czervionke","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2015.03.018_bb0130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1172\/JCI109332","article-title":"Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin","volume":"63","author":"Jaffe","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2015.03.018_bb0135","first-page":"001","article-title":"Endothelial dysfunction in young healthy men is associated with aspirin resistance","volume":"2","author":"Doroszko","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.vph.2015.03.018_bb0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0049-3848(91)90085-B","article-title":"Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients","volume":"63","author":"Grotemeyer","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.24.3.345","article-title":"Aspirin response and failure in cerebral infarction","volume":"24","author":"Helgason","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.03.018_bb0155","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.03.018_bb0160","series-title":"Platelet aggregation by ADP, collagen and ristocetin: a critical review of methodology and analysis","author":"Coller","year":"1979"},{"key":"10.1016\/j.vph.2015.03.018_bb0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.thromres.2007.04.010","article-title":"Screening for aspirin resistance in stable coronary artery patients by three different tests","volume":"121","author":"Chakroun","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0170","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1160\/TH09-08-0527","article-title":"A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease","volume":"103","author":"Grove","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0175","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidze","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2015.03.018_bb0180","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/hrt.2008.150631","article-title":"Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease","volume":"95","author":"Muir","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.vph.2015.03.018_bb0185","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.vph.2015.03.018_bb0190","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0304-4165(89)90051-2","article-title":"Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man","volume":"992","author":"Ciabattoni","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vph.2015.03.018_bb0200","doi-asserted-by":"crossref","first-page":"8384","DOI":"10.1016\/S0021-9258(19)68855-1","article-title":"Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites","volume":"256","author":"Roberts","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2015.03.018_bb0205","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.amjmed.2005.03.041","article-title":"Low-dose aspirin increases aspirin resistance in patients with coronary artery disease","volume":"118","author":"Lee","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.vph.2015.03.018_bb0210","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1160\/TH05-04-0889","article-title":"Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction","volume":"94","author":"von Pape","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-03-0186","article-title":"Immature platelets in patients with acute coronary syndromes","volume":"101","author":"Grove","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0220","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","article-title":"Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin","volume":"5","author":"Guthikonda","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0225","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2015.03.018_bb0230","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0235","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijcard.2014.05.013","article-title":"24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis","volume":"175","author":"Wurtz","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0240","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","author":"Capone","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0245","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2015.03.018_bb0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/asheducation-2007.1.114","article-title":"Aspirin and clopidogrel resistance","author":"Fitzgerald","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.vph.2015.03.018_bb0255","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1742-1241.2006.01063.x","article-title":"Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors","volume":"60","author":"Malinin","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vph.2015.03.018_bb0260","first-page":"3504","article-title":"Acetylsalicylic acid resistance\u2014clinical diagnosis with unclear mechanism","volume":"101","author":"Hillarp","year":"2004","journal-title":"Lakartidningen"},{"key":"10.1016\/j.vph.2015.03.018_bb0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.thromres.2003.12.005","article-title":"Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke","volume":"112","author":"Hillarp","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0270","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","article-title":"Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction","volume":"95","author":"Schwartz","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0275","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/00365510701601673","article-title":"No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography","volume":"68","author":"Meen","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.vph.2015.03.018_bb0280","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1538-7836.2005.01351.x","article-title":"Aspirin resistance: position paper of the Working Group on Aspirin Resistance","volume":"3","author":"Michelson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0285","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance","volume":"113","author":"Frelinger","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.03.018_bb0290","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2008.12.034","article-title":"Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration","volume":"124","author":"Hedegaard","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2015.03.018_bb0295","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review","volume":"153","author":"Hovens","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.vph.2015.03.018_bb0300","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","article-title":"Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation","volume":"46","author":"Tantry","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2015.03.018_bb0305","doi-asserted-by":"crossref","first-page":"e000703","DOI":"10.1161\/JAHA.112.000703","article-title":"High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)","volume":"1","author":"Pettersen","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.vph.2015.03.018_bb0310","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1538-7836.2008.02897.x","article-title":"Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis","volume":"6","author":"Reny","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.018_bb0315","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1161\/CIRCULATIONAHA.111.085464","article-title":"Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study","volume":"125","author":"Reny","year":"2012","journal-title":"Circulation"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T19:03:14Z","timestamp":1651690994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":63,"alternative-id":["S1537189115000683"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.03.018","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A brief review on high on-aspirin residual platelet reactivity","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}